Lanzhou Foci Pharmaceutical Co Ltd
LanZhou Foci Pharmaceutical Co.,Ltd., research and development, production, and sales of traditional chinese medicines and health products in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gelatin under the MingShan, BaoShu, BaoLu, and Foci brands. It also engages in planting and selling of Chinese medicinal materials; processing … Read more
Lanzhou Foci Pharmaceutical Co Ltd (002644) - Total Liabilities
Latest total liabilities as of September 2025: CN¥678.01 Million CNY
Based on the latest financial reports, Lanzhou Foci Pharmaceutical Co Ltd (002644) has total liabilities worth CN¥678.01 Million CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Lanzhou Foci Pharmaceutical Co Ltd - Total Liabilities Trend (2007–2024)
This chart illustrates how Lanzhou Foci Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Lanzhou Foci Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Lanzhou Foci Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Medistim ASA
OL:MEDI
|
Norway | Nkr151.23 Million |
|
Hefei Gocom Information Technology Co Ltd
SHG:688367
|
China | CN¥144.72 Million |
|
Alico Inc
NASDAQ:ALCO
|
USA | $90.50 Million |
|
JNTC Co. Ltd
KQ:204270
|
Korea | ₩295.52 Billion |
|
Shanxi Yongdong Chemistry Industry Co Ltd
SHE:002753
|
China | CN¥1.03 Billion |
|
Jiangsu Xinning Modern Logist
SHE:300013
|
China | CN¥354.76 Million |
|
METALL ZUG AG Part. Cert.
LSE:0QLX
|
UK | £188.78 Million |
Liability Composition Analysis (2007–2024)
This chart breaks down Lanzhou Foci Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.37 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lanzhou Foci Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lanzhou Foci Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual total liabilities of Lanzhou Foci Pharmaceutical Co Ltd from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥654.81 Million | -13.80% |
| 2023-12-31 | CN¥759.67 Million | -10.90% |
| 2022-12-31 | CN¥852.60 Million | +17.67% |
| 2021-12-31 | CN¥724.59 Million | -9.44% |
| 2020-12-31 | CN¥800.08 Million | -10.48% |
| 2019-12-31 | CN¥893.78 Million | -17.52% |
| 2018-12-31 | CN¥1.08 Billion | +9.38% |
| 2017-12-31 | CN¥990.68 Million | +32.78% |
| 2016-12-31 | CN¥746.13 Million | +479.45% |
| 2015-12-31 | CN¥128.77 Million | -58.65% |
| 2014-12-31 | CN¥311.40 Million | +55.93% |
| 2013-12-31 | CN¥199.70 Million | +35.50% |
| 2012-12-31 | CN¥147.38 Million | -18.64% |
| 2011-12-31 | CN¥181.14 Million | +39.67% |
| 2010-12-31 | CN¥129.70 Million | -23.30% |
| 2009-12-31 | CN¥169.09 Million | -7.96% |
| 2008-12-31 | CN¥183.70 Million | +11.53% |
| 2007-12-31 | CN¥164.72 Million | -- |